316 related articles for article (PubMed ID: 12548159)
21. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2010; 54(3):277-82. PubMed ID: 20518411
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma.
Saad RS; Cho P; Silverman JF; Liu Y
Am J Clin Pathol; 2004 Sep; 122(3):421-7. PubMed ID: 15362373
[TBL] [Abstract][Full Text] [Related]
23. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
24. CDX-2 Expression in Primary Lung Adenocarcinoma.
Cowan ML; Li QK; Illei PB
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
[TBL] [Abstract][Full Text] [Related]
25. [Expression of Cdx-2 homeobox gene in intestinal metaplasia and gastric adenocarcinoma].
Paik CH; Han DS; Lee SH; Chung YW; Kim JP; Sohn JH; Hahm JS; Oh YH; Park YU
Korean J Gastroenterol; 2004 Oct; 44(4):186-92. PubMed ID: 15505429
[TBL] [Abstract][Full Text] [Related]
26. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
27. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.
Compérat E; Zhang F; Perrotin C; Molina T; Magdeleinat P; Marmey B; Régnard JF; Audouin J; Camilleri-Broët S
Mod Pathol; 2005 Oct; 18(10):1371-6. PubMed ID: 15861215
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas.
Inamura K; Satoh Y; Okumura S; Nakagawa K; Tsuchiya E; Fukayama M; Ishikawa Y
Am J Surg Pathol; 2005 May; 29(5):660-5. PubMed ID: 15832091
[TBL] [Abstract][Full Text] [Related]
29. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.
Chou YY; Jeng YM; Kao HL; Chen T; Mao TL; Lin MC
Histopathology; 2003 Aug; 43(2):151-6. PubMed ID: 12877730
[TBL] [Abstract][Full Text] [Related]
31. Among sinonasal tumors, CDX-2 immunoexpression is not restricted to intestinal-type adenocarcinomas.
Tilson MP; Gallia GL; Bishop JA
Head Neck Pathol; 2014 Mar; 8(1):59-65. PubMed ID: 23846317
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
33. CDX-2, a new marker for adenocarcinoma of gastrointestinal origin.
Li MK; Folpe AL
Adv Anat Pathol; 2004 Mar; 11(2):101-5. PubMed ID: 15090846
[TBL] [Abstract][Full Text] [Related]
34. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
35. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: III. Expressions of EMA, CEA, CA19-9, CDX-2, p53, Ki-67 antigen, TTF-1, vimentin, and p63 in normal mucosa and in 42 cases.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):630-8. PubMed ID: 23573309
[TBL] [Abstract][Full Text] [Related]
36. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
37. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
Tot T
Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
[TBL] [Abstract][Full Text] [Related]
38. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions.
Kim HS; Lee JS; Freund JN; Min KW; Lee JS; Kim W; Juhng SW; Park CS
J Gastroenterol Hepatol; 2006 Feb; 21(2):438-42. PubMed ID: 16509871
[TBL] [Abstract][Full Text] [Related]
39. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].
Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693
[TBL] [Abstract][Full Text] [Related]
40. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
Strickland-Marmol LB; Khoor A; Livingston SK; Rojiani A
Arch Pathol Lab Med; 2007 Nov; 131(11):1686-90. PubMed ID: 17979487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
